Healthy Opioid Prescription Engagement

Description

This study is a randomized controlled trial across 14 community pharmacies to test the efficacy of the Brief Intervention-Medication Therapy Management intervention (BI-MTM). The establishment of the BI-MTM model will result in a major impact for addressing the opioid epidemic, preventing opioid use disorder and overdose, and safeguarding patient health in a novel community-based service setting.

Conditions

Opioid Misuse, Opioid-Related Disorders, Pharmacist-Patient Relations

Study Overview

Study Details

Study overview

This study is a randomized controlled trial across 14 community pharmacies to test the efficacy of the Brief Intervention-Medication Therapy Management intervention (BI-MTM). The establishment of the BI-MTM model will result in a major impact for addressing the opioid epidemic, preventing opioid use disorder and overdose, and safeguarding patient health in a novel community-based service setting.

Healthy Opioid Prescription Engagement 2.0

Healthy Opioid Prescription Engagement

Condition
Opioid Misuse
Intervention / Treatment

-

Contacts and Locations

Salt Lake City

University of Utah, Salt Lake City, Utah, United States, 84108

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult (≥18 years)
  • * English speaking
  • * Not receiving cancer treatment
  • * Who have a positive opioid misuse screen on the POMI will be eligible to learn about this study
  • * Are pregnant (given potential pre/post-natal opioid use complications among pregnant women/offspring
  • * Can-not provide collateral contact information for ≥2 contact persons (to ensure consistent contact/follow up)
  • * Do not have a reliable land line or mobile phone to be contacted by study staff
  • * Are filling only buprenorphine (given some formulations are not indicated for pain)
  • * Plan to leave the area for an extended period of time in the next 6 months
  • * Have had a psychotic and/or manic episode in the last 30 days (before consent, patients will be asked to screen for psychosis
  • * Do not provide permission to access their state prescription drug monitoring data.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Jerry Cochran,

Gerald Cochran, PhD, PRINCIPAL_INVESTIGATOR, University of Utah

Study Record Dates

2026-12-01